Dealmakers' Intentions

Many resources available to business development professionals provide retrospective data regarding deal activity in the pharmaceutical and biotech industry. These indispensable tools, including libraries of financing transactions, deal databases, and royalty rate studies, provide timely information on deal activity as transactions are closed and announced. However, because deals often take more than a year to complete, these databases may not be good indicators of emerging strategies or the future deal environment.

 

The Dealmakers’ Intentions Study conducted by Syneos Health Consulting is intended to provide a glimpse into future dealmaking. Business development professionals from pharmaceutical and biotechnology companies of all sizes are surveyed around the beginning of the new year. They are asked questions about their general expectations for deal activity in the coming year and the intentions of their own company for areas of focus. Questions are also included about the operations and organizational design approaches of their companies, as well as key market forces influencing their decision-making. Finally, information is collected regarding dealmakers’ perspectives on key emerging topics. This is an annual survey, allowing a comparison of responses over time. In fact, we find the most powerful use of the survey comes from comparing responses over time and building insights based on emerging intentions and coupling these observations with demonstrated deal activity.

 

Download the 2018 Dealmaker's Intentions Study white paper here.

 

If you would like for us to present the full results to your team, please Contact Us

Contact Us
Call Our Team 

Phone: +1 919 876 9300
Fax: +1 919 876 9360
Toll-Free: +1 866 462 7373

Corporate Headquarters

3201 Beechleaf Court
Suite 600
Raleigh, NC 27604-1547